Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Function of hyperekplexia-causing α1R271Q/L glycine receptors is restored by shifting the affected residue out of the allosteric signalling pathway.
Shan Q
,
Han L
,
Lynch JW
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE Glycine receptor α1 subunit R271Q and R271L (α1R271Q/L) mutations cause the neuromotor disorder, hereditary hyperekplexia. Studies suggest that the 271 residue is located within the allosteric signalling pathway linking the agonist binding site to the channel gate. The present study aimed to investigate a possible mechanism for restoring the function of the α1R271Q/L glycine receptor. EXPERIMENTAL APPROACH A 12-amino-acid segment incorporating the 271 residue on the glycine receptor α1271Q/L subunit was replaced by the homologous segment from the glycine receptor β subunit (α1(Ch) 271Q/L). The function of the α1(Ch) 271Q/L glycine receptor was examined by whole-cell patch-clamp recording and voltage-clamp fluorometry techniques. KEY RESULTS The function of the α1(Ch) 271Q/L glycine receptor was restored to the level of the wild-type (WT) α1 glycine receptor. Moreover, in the α1(Ch) glycine receptor, in contrast to the α1 glycine receptor, the channel function was not sensitive to various substitutions of the 271 residue, and the conformational change in the vicinity of the 271 residue was uncoupled from the channel gating. CONCLUSIONS AND IMPLICATIONS The 271 residue is shifted out of the allosteric signalling pathway in the α1(Ch) glycine receptor. We propose that this mechanism provides a novel drug design strategy not only for glycine receptor α1R271Q/L-caused hereditary hyperekplexia, but also for any pathological condition that is caused by missense mutation- or covalent modification-induced disorders involving residues in allosteric signalling pathways. Such a strategy makes it possible to design an ideal drug, which only corrects the function of the mutant or modified protein without affecting the WT or naive protein.
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011, Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011,
Pubmed
Bakker,
Clonazepam is an effective treatment for hyperekplexia due to a SLC6A5 (GlyT2) mutation.
2009,
Pubmed
Bocquet,
X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation.
2009,
Pubmed
Bouzat,
Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel.
2004,
Pubmed
Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed
Browne,
Clonazepam. A review of a new anticonvulsant drug.
1976,
Pubmed
Bykov,
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
2002,
Pubmed
Bykov,
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.
2002,
Pubmed
Chung,
Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia.
2010,
Pubmed
Collins,
Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.
2010,
Pubmed
,
Xenbase
Colquhoun,
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.
1998,
Pubmed
Franks,
General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal.
2008,
Pubmed
Gandhi,
Shedding light on membrane proteins.
2005,
Pubmed
Grudzinska,
The beta subunit determines the ligand binding properties of synaptic glycine receptors.
2005,
Pubmed
Harvey,
The genetics of hyperekplexia: more than startle!
2008,
Pubmed
Hibbs,
Principles of activation and permeation in an anion-selective Cys-loop receptor.
2011,
Pubmed
Hilf,
X-ray structure of a prokaryotic pentameric ligand-gated ion channel.
2008,
Pubmed
Hilf,
Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel.
2009,
Pubmed
Hosie,
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites.
2006,
Pubmed
Joerger,
Structure-function-rescue: the diverse nature of common p53 cancer mutants.
2007,
Pubmed
Kar,
Allostery and population shift in drug discovery.
2010,
Pubmed
Kumar,
Folding and binding cascades: dynamic landscapes and population shifts.
2000,
Pubmed
Lambert,
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
2009,
Pubmed
Langosch,
Decreased agonist affinity and chloride conductance of mutant glycine receptors associated with human hereditary hyperekplexia.
1994,
Pubmed
,
Xenbase
Lee,
Binding to gating transduction in nicotinic receptors: Cys-loop energetically couples to pre-M1 and M2-M3 regions.
2009,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Lummis,
Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel.
2005,
Pubmed
Lynagh,
A glycine residue essential for high ivermectin sensitivity in Cys-loop ion channel receptors.
2010,
Pubmed
Lynch,
The surface accessibility of the glycine receptor M2-M3 loop is increased in the channel open state.
2001,
Pubmed
Lynch,
Molecular structure and function of the glycine receptor chloride channel.
2004,
Pubmed
Lynch,
Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel.
1997,
Pubmed
Mihic,
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors.
1997,
Pubmed
,
Xenbase
Miller,
Binding, activation and modulation of Cys-loop receptors.
2010,
Pubmed
Nury,
X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel.
2011,
Pubmed
Nussinov,
Allosteric modulators can restore function in an amino acid neurotransmitter receptor by slightly altering intra-molecular communication pathways.
2012,
Pubmed
O'Shea,
Propofol restores the function of "hyperekplexic" mutant glycine receptors in Xenopus oocytes and mice.
2004,
Pubmed
,
Xenbase
Pless,
Conformational variability of the glycine receptor M2 domain in response to activation by different agonists.
2007,
Pubmed
,
Xenbase
Pless,
Illuminating the structure and function of Cys-loop receptors.
2008,
Pubmed
Rajendra,
Startle disease mutations reduce the agonist sensitivity of the human inhibitory glycine receptor.
1994,
Pubmed
Rajendra,
Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists.
1995,
Pubmed
Rees,
Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease.
2006,
Pubmed
,
Xenbase
Shan,
Asymmetric contribution of alpha and beta subunits to the activation of alphabeta heteromeric glycine receptors.
2003,
Pubmed
Shan,
A single beta subunit M2 domain residue controls the picrotoxin sensitivity of alphabeta heteromeric glycine receptor chloride channels.
2001,
Pubmed
Shan,
Ivermectin, an unconventional agonist of the glycine receptor chloride channel.
2001,
Pubmed
Shan,
Chimera construction using multiple-template-based sequential PCRs.
2010,
Pubmed
Sinha,
Point mutations and sequence variability in proteins: redistributions of preexisting populations.
2001,
Pubmed
Thompson,
The structural basis of function in Cys-loop receptors.
2010,
Pubmed
Todd,
The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease.
1999,
Pubmed
Unwin,
Refined structure of the nicotinic acetylcholine receptor at 4A resolution.
2005,
Pubmed
Wang,
Restoring p53-dependent tumor suppression.
2003,
Pubmed
Zhou,
Hyperekplexia: a treatable neurogenetic disease.
2002,
Pubmed
del Sol,
The origin of allosteric functional modulation: multiple pre-existing pathways.
2009,
Pubmed
